Coagulation profiles and thromboembolic events of bortezomib plus thalidomide and dexamethasone therapy in newly diagnosed multiple myeloma

被引：16
作者：
Shen, Yunfeng [1 ]
Zhou, Xin [1 ]
Wang, Zhi [2 ]
Yang, Guohua [1 ]
Jiang, Yuanqiang [1 ]
Sun, Chao [1 ]
Wang, Jing [1 ]
Tong, Yi [1 ]
Guo, Hongfeng [1 ]
机构：
[1] Nanjing Med Univ, Wuxi Peoples Hosp, Dept Hematol, Wuxi 214023, Peoples R China
[2] Nanjing Med Univ, Wuxi Peoples Hosp 2, Dept Hematol, Wuxi, Peoples R China
来源：
LEUKEMIA RESEARCH | 2011年 / 35卷 / 02期
关键词：
Bortezomib; Multiple myeloma; Hematological toxicity; Thromboembolic event; Coagulation; Thalidomide; VENOUS THROMBOEMBOLISM; EFFECTIVE REGIMEN; HUMAN PLATELETS; COMBINATION; THROMBOSIS; EXPERIENCE; MELPHALAN; VTD;
D O I：
10.1016/j.leukres.2010.08.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Patients with multiple myeloma (MM) are at relatively high risk of developing thromboembolic event (TEE), especially during treatment with immnomodulatory agents. We characterized coagulation profiles and evaluate the incidence of TEE associated with the combination therapy of bortezomib-thalidomide-dexamethasone (VTD) in Chinese patients with newly diagnosed MM. The results indicated that the platelet count and platelet aggregation induced by the agonists were decreased after a short exposure to bortezomib in vivo. The incidence of TEE was low in VTD therapy for an overall rate of 3%. We do not recommend routine thromboprophylaxis for VTD therapy in Chinese patients with MM. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码：147 / 151
页数：5
相关论文
共 27 条
[1]   Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro [J].
Avcu, Ferit ;
Ural, A. Ugur ;
Cetin, Turker ;
Nevruz, Oral .
THROMBOSIS RESEARCH, 2008, 121 (04) :567-571
[2]   Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma [J].
Badros, Ashraf ;
Goloubeva, Olga ;
Fenton, Robert ;
Rapoport, Aaron P. ;
Akpek, Gorgun ;
Harris, Carolynn ;
Ruehle, Kathleen ;
Westphal, Sandra ;
Meisenberg, Barry .
CLINICAL LYMPHOMA & MYELOMA, 2006, 7 (03) :210-216
[3]   Thalidomide-associated deep vein thrombosis and pulmonary embolism [J].
Bennett, CL ;
Schumock, GT ;
Desai, AA ;
Kwaan, HC ;
Raisch, DW ;
Newlin, R ;
Stadler, W .
AMERICAN JOURNAL OF MEDICINE, 2002, 113 (07) :603-606
[4]  
Chan MHH, 2005, BLOOD, V106, p370B
[5]  
Chan Y K, 2004, J Orthop Surg (Hong Kong), V12, P178
[6]   Epidemiology of venous thromboembolism in a Chinese population [J].
Cheuk, BLY ;
Cheung, GCY ;
Cheng, SWK .
BRITISH JOURNAL OF SURGERY, 2004, 91 (04) :424-428
[7]   A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma [J].
Chim, C. S. ;
Lie, A. K. W. ;
Chan, E. Y. T. ;
Leung, Y. Y. ;
Cheung, S. C. W. ;
Chan, S. Y. T. ;
Liang, Raymond ;
Kwong, Y. L. .
ANNALS OF HEMATOLOGY, 2010, 89 (10) :1019-1027
[8]   Low dose velcade, thalidomide and dexamethasone (LD-VTD): An effective regimen for relapsed and refractory multiple myeloma patients [J].
Ciolli, S ;
Leoni, F ;
Gigli, F ;
Rigacci, L ;
Bosi, A .
LEUKEMIA & LYMPHOMA, 2006, 47 (01) :171-173
[9]   Bortezomib A Review of its Use in Patients with Multiple Myeloma [J].
Curran, Monique P. ;
McKeage, Kate .
DRUGS, 2009, 69 (07) :859-888
[10]   Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP) [J].
Eom, Hyeon-Seok ;
Kim, Yeo-Kyeoung ;
Chung, Joo-Seop ;
Kim, Kihyun ;
Kim, Hyo Jung ;
Kim, Ho Young ;
Jin, Jong-Youl ;
Do, Young-Rok ;
Oh, Suk-Joong ;
Suh, Cheolwon ;
Seong, Chu-Myong ;
Kim, Chul Soo ;
Lee, Dong Soon ;
Lee, Jae Hoon .
ANNALS OF HEMATOLOGY, 2010, 89 (05) :489-497
123